Complete biotherapeutic characterization BioPharma Finder Software

Significance of the topic

BioPharma Finder software provides an integrated, workflow-driven LC–MS data processing environment tailored for comprehensive biotherapeutic characterization. High-resolution mass spectrometry (HRAM) and advanced data algorithms are essential for confident identification, quantitation, and monitoring of product and process-related attributes (PQAs/HCPs/CQAs). Automated, reproducible analysis accelerates R&D, supports method development (including MAM), and enables high-throughput monitoring required across development, QC non-regulated screening, and process analytics.

Study goals and overview

This document presents the scope, capabilities, and practical workflows provided by BioPharma Finder to transform raw MS data into actionable information for peptide mapping, intact and subunit mass analysis, top-/middle-down proteoform characterization, oligonucleotide and mRNA mapping, HCP identification and quantitation, HDX analysis, and MAM-style monitoring. The emphasis is on automation, sensitivity for low-abundance components, and streamlined data visualization and reporting via integration with the Ardia Platform and Chromeleon CDS.

Applied methodology and workflow features

BioPharma Finder implements end-to-end workflows combining spectrum processing, component detection, deconvolution, MS² prediction/matching, and automated reporting. Key methodological features include:

• Sliding Window deconvolution for retention-time-resolved deconvolution and enhanced detection of low-abundance and coeluting species.
• Dual deconvolution engines: isotopically-resolved Xtract algorithm and unresolved-signal ReSpect algorithm to cover small oligonucleotides through intact proteins and large assemblies.
• Automated MS² processing with predicted fragment spectra for peptides and a kinetic fragmentation model for oligonucleotides to improve fragment matching and sequence confirmation.
• Built-in, workflow-driven processing templates for peptide mapping, disulfide mapping, HCP workflows, HDX, intact/subunit analysis, top-/middle-down, oligonucleotide sequencing, and mRNA mapping (in silico digestion).
• Batch processing and multi-file consensus analyses to speed throughput and compare multiple conditions/samples in a single operation.
• Interactive visualization tools: fragment coverage maps, annotated MS² spectra, chromatographic shading of component classes, modification plots, and protection-factor plots for HDX.
• Support for custom sequence building blocks and user-defined variable modifications for oligonucleotide and protein analyses, plus randomized-sequence generation to aid specificity assessment.

Used Instrumentation

The software is designed to work with Thermo Fisher mass spectrometry platforms and related software tools, with explicit support and examples for:

• Thermo Scientific Orbitrap family mass analyzers (HRAM data leverage for highest confidence).
• Q Exactive UHMR Hybrid Quadrupole-Orbitrap instrument for intact/glycosylated molecules and high-mass analyses.
• Ion trap and quadrupole data compatibility for diverse data sources.
• Thermo Scientific Chromeleon Chromatography Data System (CDS) for exporting PQA/CQA monitoring targets and compliant workflows.
• Thermo Scientific ProSightPC algorithms for MS² searches in top-down workflows; ReSpect and Xtract deconvolution engines for unresolved and resolved data.
• Ardia Platform for file centralization, versioning, remote collaboration, and report management.

Main results and discussion

BioPharma Finder consolidates multiple analytical tasks into a single environment and demonstrates the following practical outcomes:

• High peptide-map coverage including detection of sequence variants and PTMs (oxidation, deamidation, glycosylation) using combined MS and MS² matching, boosting identification confidence and enabling near-complete sequence coverage.
• Superior component detection that uncovers low-level impurities and new peaks across comparative sample sets, with quantitative metrics (ratios, min/max, MS area) to flag changes beyond acceptance criteria.
• Robust HCP workflows that identify product peptides, search unidentified MS² spectra against organism-specific databases (CHO, human, mouse), and automatically select peptides for relative quantitation to assess purification efficiency.
• Accurate intact mass and subunit characterization using optimized deconvolution approaches; Sliding Window improves detection of coeluting and low-abundance variants, and enables sensitive DAR and ADC analyses down to low percent levels.
• Enhanced oligonucleotide and mRNA characterization through custom building blocks, variable modification searching, predicted MS² (including intensity predictions via a kinetic model), terminal truncation searching, and in silico RNase digestion tools for mRNA mapping.
• Top-/middle-down workflows that support multiple fragmentation modes (CID, HCD, ETD, EThcD, UVPD), process up to ten files in consensus, and facilitate proteoform definition and comparison with flexible visualization and per-peak deconvolution settings.
• Improved throughput via automated parameter optimization, batch processing, multi-sample consensus reporting, and export options for downstream compliant monitoring in Chromeleon CDS.

Benefits and practical applications

BioPharma Finder delivers tangible benefits to analytical and biopharma labs:

• Streamlined workflows reduce manual parameter tuning and accelerate time-to-result for peptide mapping, intact mass, oligonucleotide sequencing, and top-down analyses.
• Higher sensitivity and confidence for low-abundance species and coeluting variants help ensure detection of critical quality attributes and process-related impurities.
• Integrated HCP identification and quantitation support upstream/downstream process assessment and purification validation.
• Flexible export to Chromeleon CDS facilitates transition from characterization to routine monitoring in regulated or semi-regulated environments.
• Ardia Platform integration improves data governance with versioning, centralized file management, and customizable reporting templates—beneficial for collaboration and auditability.
• Support for diverse fragmentation modes and deconvolution algorithms enables characterization of a broad range of analytes from small oligonucleotides to large protein assemblies and even viral particles.

Future trends and potential applications

BioPharma Finder’s capabilities align with several evolving trends in biopharma analytics and suggest future expansion paths:

• Greater automation and AI-driven parameter optimization for improved sensitivity and reduced operator dependence.
• Deeper integration with laboratory informatics ecosystems (LIMS, ELN, CDS) and cloud-based platforms for collaborative multi-site studies and reproducible recordkeeping.
• Advances in fragmentation modeling and spectral prediction—especially for modified oligonucleotides and complex proteoforms—will further increase sequence-confirmation confidence.
• Expanded quantitative MAM workflows with automatic transfer of PQA lists to compliant CDS systems will support broader adoption in QC environments.
• Continued refinement of native MS and intact-mass deconvolution methods for higher-mass complexes may enable routine characterization of ever-larger assemblies and biologic modalities.

Conclusion

BioPharma Finder provides a comprehensive, workflow-oriented software suite enabling confident, high-throughput characterization of biotherapeutics. By combining advanced deconvolution algorithms, MS²-driven sequence confirmation, oligonucleotide-specific tools, and robust visualization with Ardia Platform connectivity, the software reduces manual effort, improves detection of low-level and coeluting species, and supports the transition from discovery to routine monitoring. These capabilities position it as a central tool for analytical laboratories focused on product understanding, method development, and PQA/CQA tracking.